Table 3.
Compound | Cell Lines IC50 (μg/mL) | ||
---|---|---|---|
A549 a | DLD-1 b | P388D1 c | |
1 | 9.7 ± 1.2 | 6.0 ± 0.4 | 7.2 ± 1.8 |
2 | 28.6 ± 3.8 | 31.6 ± 3.7 | 30.4 ± 4.8 |
3 | − d | − | 19.6 ± 8.3 |
4 | − | − | − |
5 | − | − | − |
6 | − | − | − |
7 | 10.8 ± 4.9 | 11.7 ± 4.8 | 8.9 ± 2.2 |
Doxorubicin e | 0.3 ± 0.1 | 1.5 ± 0.2 | 0.9 ± 0.2 |
a A549: Human lung adenocarcinoma. b DLD-1: Human colorectal adenocarcinoma. c P388D1: Mouse lymphocytic leukemia cell line. d IC50 > 40 μg/mL. e Clinical anticancer drug used as a positive control.